69 research outputs found
Innovative drugs for the treatment of primary headaches: migraine
The article presents information about innovative drugs for the treatment of primary headaches (in particular, migraine), which are at the stages of clinical or preclinical studies, or were recently introduced to the foreign pharmaceutical market. The classes of these drugs, their mechanism of action, as well as the results of past studies are presents in article
Quality assessment of pharmaceutical care to patients with headaches using the simulated patient method: interaction practice
Relevance. WHO assesses headaches as a global world problem. Russia occupies a leading position in the prevalence of primary headaches. Headaches are one of the most common reasons for visiting a pharmacy for self-medication. The interaction of the pharmacist and the visitor with the headache problem in general determines the quality of pharmaceutical care.Aim. To assess the practice of the interaction between a patient with a headache and a pharmacist using the simulated patient method.Materials and methods. Trained simulated patients (women aged 20, 40 and 58 years) visited a total of 101 pharmacies. The dialogue was recorded on a voice recorder, all the features of the interaction were additionally recorded aο¬
er the visit. Special forms were ο¬lled out based on the information received. The data was processed using Microsoο¬
Excel 2010 and STATISTIKA 10.0.Results. The average interaction time was 98.2Β±3.8 seconds. There was a high frequency of spontaneous recommendations without preliminary questions (66.3%), a small number of questions asked (0.84Β±0.1). These indicators practically did not depend on various factors (type of pharmacy organization, age of the pharmacist, age of the simulated patient, the presence of a queue, and others).Conclusion. The results of the study demonstrate a low level of interaction between pharmacists and visitors with a headache, as well as a practical absence of involvement in the process of providing pharmaceutical care, which negatively aο¬ects its quality: frequent spontaneous recommendations, short consultations and rare questions. The approach to the interaction of pharmacists with visitors with headaches is formal and requires standardization
Quality assessment of pharmaceutical care to patients with headaches using the simulated patient method: drug recommendations and pharmaceutical counseling
Relevance. Headaches are one of the most important health problems both in Russia and around the world, as well as one of the most common reasons for self-treatment in a pharmacy due to the availability of over-the-counter drugs. Pharmaceutical workers play an important role in the control of self-medication, and the rationality of drug recommendations determines the quality of pharmaceutical care.Aim. To assess the rationality of drug recommendations for a patient with a headache and pharmaceutical drug counseling using the simulated patient method.Materials and methods. Trained simulated patients (women aged 20, 40 and 58 years) visited a total of 101 pharmacies. The dialogue was recorded on a voice recorder, all the features of the interaction were additionally recorded aο¬
er the visit. Special forms were ο¬lled out based on the information received. The data was processed using Microsoο¬
Excel 2010 and STATISTIKA 10.0.Results. There was a high frequency of spontaneous recommendations without preliminary questions (66.3%), recommendations (14.9%) and dispensing of prescription drugs (5.0%), frequent recommendations of combined drugs (91.0%). Trade name Pentalgin (46.5%) and trade name Nurofen (42.6%), INN Ibuprofen (47.5%) were the most recommended. Combination analgesics were purchased in most of the visits (72.0%), information on the duration of use of the drug and the need to visit a doctor was never provided.Conclusion. Pharmacists' recommendations are in most cases irrational, focused on the drug as a product and sometimes unsafe, and counseling is practically non-existent. Improving the quality of pharmaceutical care at this stage should include the development of standards for drug recommendations and adequate counseling
Modern aspects of epidemiology of congenital anomalies of development: methodological issues and the translation of research fndings into clinical practice
Progress achieved in the identifcation and characterization of the risk factors for congenital anomalies occur mainly from epidemiological studies, which gave many associations between risk factors and groups of birth defects. However, in clinical practice the transmission of these associations as the actual reasons remains very difcult. Characteristics and epidemiological analysis of possible factors, including drugs, associated with the occurrence of congenital anomalies, are crucial for the development of prevention activities that have an impact on the incidence of defects. To further reduce the global burden of birth defects can help the integration of studies in epidemiology, genetics and epigenetics through personalized and population oriented preventive strategies
The rationality of recommendations of drugs for patients with cephalgia in simulated situations in the pharmacy
Relevance. According to statistics of the World Health Organization, at least half of the worldβs adult population experienced headaches at least once a year. Patients suffering from headaches do not always have the opportunity to visit a doctor, therefore, an important role in helping these patients is assigned to pharmacists. Purpose. Based on the pharmacoepidemiological study to identify the features of providing pharmaceutical care to patients with headache in pharmacies in the issue of rationality of recommendations of pharmaceutical workers. Materials and methods. A pharmacoepidemiological study was conducted based on a survey of 153 pharmaceutical workers (Saratov) using a specially developed questionnaire that includes free-form questions with a simulated situation. The data was processed using Microsoft Excel 2010 and STATISTIKA 6.0. Results Of the groups recommended to visitors, INNs in the group Β«Nonsteroidal anti-inflammatory and antirheumatic drugs [M01A]Β» account for 45.0 % of all INNs, and the group Β«Analgesics [N02]Β» - 55.0 %. Ibuprofen (62.8 %) and the combination of drotaverine + caffeine + naproxen + paracetamol + phenylephrine (41.2 %) were noted as the most frequently recommended. A visit to a doctor was recommended by the majority of respondents (52.3 %, n=153) in the case of a patient with a headache accompanied by nausea and vomiting. Ibuprofen (90.8 %) or paracetamol (45.8 %), moreover in the form of suspension or suppositories, are the preferred recommendations for headache in children under 3 years of age (n=131). Paracetamol in combinations (69.2 %) prevails as the first recommendation for headache associated with acute respiratory viral infections (n??=146). Non-selective NSAIDs for a patient with gastrointestinal complications could be recommended by 43.4 % of specialists (n=113). The NSAID recommendation is the most frequent (51.8 %, n=110) in the case of an 80-year-old patient without concomitant diseases. Paracetamol (50.0 %) or ibuprofen (34.7 %) would be more often recommended by pharmaceutical workers for a pregnant woman with headache (n=98). In case of headache after trauma, 47.1 % recommend a visit to a doctor (n=153). Conclusion. The frequent recommendation of combined analgesics and their association with the development of drug-induced headaches indicates the need for careful recommendation of these drugs. Not always correct recommendations indicate the need to increase the level of professional knowledge, study clinical recommendations for the therapy and diagnosis of cephalgia, which can make it possible to make a rational choice of the drug, initially assume that the visitor has conditions that require a visit to a doctor, and ultimately improve the quality of pharmaceutical care
Evaluation of adherence of patients with atrial fibrillation to anticoagulant therapy at the outpatient stage of treatment
Despite clinical guidelines for the treatment of atrial fibrillation (AF) patient adherence to oral anticoagulants (OACs) in routine clinical practice remains low. Assessing the factors affecting adherence to the OACs regimen and developing strategies for its improvement is important. Aim. To assess the adherence of patients with AF to the prescribed anticoagulant therapy at the outpatient stage of treatment. Methodology. The object of the study was 165 patients with nonvalvular AF undergoing treatment in a specialized cardiology department or receiving outpatient treatment in a specialized cardiological dispensary in Saratov from February 2018 to December 2019. After 3, 6, 12 months, a telephone contact with the patients was carried out, a specially designed questionnaire was filled out, in which the anticoagulant therapy received by AF patients was reflected, the Morisky-Green questionnaire was filled out, the answers of patients about the reasons for skipping or stopping the administration of the OACs were recorded. Results. After 3 months. 16.6 % of AF patients replaced the OACs intake with antiplatelet agents, 16 % refused antithrombotic therapy; 43.1 % of AF patients were adherent to OACs. After 6 months. antiplatelet agents were taken by 24.5 % patients (p<0.05), 11.9 % completely stopped taking antithrombotic drugs; 30.8 % of patients were adherent to OACs (p<0.05). After 12 29,5 % patients replaced OACs treatment with antiplatelet agents, 7.6 % patients did not take any antithrombotic drugs; 31.8 % of AF patients were adherent to OACs. The most common reasons for a decrease in the adherence to OACs therapy were the cost of drugs, lack of understanding of the value of OACs administration in AF, and the lack of appreciable effect of OACs administration. Conclusion. At the outpatient stage of treatment, there was an insufficient level of adherence of AFpatients to OACs treatment
Analysis of antithrombotic therapy of atrial fibrillation in international and Russian registries
In the article the features of the organization of international and Russian registers of patients with atrialΒ fibrillation (AF), the clinical and demographic characteristics of patients included in the registers, as well as the featuresΒ of antithrombotic therapy of AF and its compliance with current clinical guidelines were observed. In a number of largeΒ randomized controlled trials (RCTs), not less effectiveness, and in some cases, the superiority of direct oral anticoagulantsΒ (DOACs) over warfarin, were proved in the prevention of ischemic insulin stroke patients with non-valvular AF with betterΒ safety profile and ease of use. However, the problem of the use of data obtained during RCTs in real clinical practice, for theΒ solution of which medical registers are gaining much popularity, remains relevant. The article provides an analysis of 16Β prospective multicenter international and Russian registers of patients with AF. For convenience of comparison, registersΒ were divided into three groups in accordance with the features of the organization and inclusion criteria. UnambiguousΒ conclusions were drawn about the incompatibility of the real clinical practice of antithrombotic therapy of AF withΒ current clinical recommendations. Differences in the population of patients with AF in Russia compared with EuropeanΒ countries were found, which led to the conclusion that insufficient detection of AF at the outpatient stage of diagnosis andΒ the resulting inappropriate anticoagulant therapy aiming the prevention of stroke and ischemic complications take place,Β which may be due to the differences in the socioeconomic status of the regions and the characteristics of the organizationΒ of medical treatment and preventive care to the population
ΠΠ½Π°Π»ΠΈΠ· ΠΎΠ±ΡΠ΅ΠΌΠΎΠ² ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΏΡΠΈΡ ΠΎΡΡΠΎΠΏΠ½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΠΈ, Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ°
the goal of our research was to carry out an analysis of psychotropic drug utilization used for patients with schizophreniaΒ in two (state and municipal) in-patient clinics during 2000 and 2010, using the DDD methodology. As the result, we found out thatΒ psychotropic drug utilization increased from 2000 to 2010 in both types of in-patient clinics. Consumption of second-generationΒ antipsychotics increase in state clinic in 2010. And in the state clinic we can observe a favorable trend in the decrease of antidepressantsΒ and tranquilizers consumption.ΠΎΡΠΊΡΡΡΠΎΠ΅ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
Β ΡΡΠ΅Π΄ΡΡΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΠΈ, ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡΒ Π² 2000-2010 Π³Π³. Π¦Π΅Π»Ρ: ΡΠ΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΠ±ΡΠ΅ΠΌΠΎΠ² ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
Β ΡΡΠ΅Π΄ΡΡΠ² (ΠΠ‘), ΠΏΡΠΈΠΌΠ΅Π½ΡΠ²ΡΠΈΡ
ΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠ°Π½ΠΎΠΈΠ΄Π½ΠΎΠΉ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΠΈ Π² Π΄Π²ΡΡ
ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ
ΡΠ°Π·Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° Π² 2000 ΠΈ 2010 Π³Π³. Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ Β«ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ
Π΄Π½Π΅Π²Π½ΡΡ
Π΄ΠΎΠ·Β». ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ Π΄Π΅ΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π΄ΠΈΠ°Π³Π½ΠΎΠ·,Β ΡΠΈΠ½Π΄ΡΠΎΠΌ, ΡΠΈΠΏ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ,Β Π²ΠΎΠ·ΡΠ°ΡΡ Π½Π°ΡΠ°Π»Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ; Π½Π°Π·Π²Π°Π½ΠΈΡ Π½Π΅ΠΉΡΠΎΠ»Π΅ΠΏΡΠΈΠΊΠΎΠ² (ΠΠ) ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΠΎΠΏΡΡΡΡΠ²ΡΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Ρ ΡΠΊΠ°Π·Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅ΠΆΠΈΠΌΠ° ΠΈΡ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ (Π΄ΠΎΠ·Π°, ΠΊΡΠ°ΡΠ½ΠΎΡΡΡ, ΠΏΡΡΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ), Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈΒ Β«ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ
Π΄Π½Π΅Π²Π½ΡΡ
Π΄ΠΎΠ·Β» (Defined Daily Doses β DDD). Π’Π°ΠΊΠΆΠ΅Β ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈΡΡ ΠΏΠΎΠ±ΠΎΡΠ½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΡ ΠΏΡΠΈΡ
ΠΎΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΈΡΡ
ΠΎΠ΄Β Π»Π΅ΡΠ΅Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ, ΡΡΠΎ ΠΎΠ±ΡΠ΅ΠΌΡ ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΏΡΠΈΡ
ΠΎΡΡΠΎΠΏΠ½ΡΡ
ΠΠ‘ ΠΏΡΠΈ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΡΠΈΠ·ΠΎΡΡΠ΅Π½ΠΈΠΈ Π²ΡΡΠΎΡΠ»ΠΈ ΡΒ 2000 ΠΏΠΎ 2010 Π³., Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ ΡΠΈΠΏΠ° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°. ΠΠ±ΡΠ΅ΠΌΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π°ΡΠΈΠΏΠΈΡΠ½ΡΡ
ΠΠ Π² 2010 Π³. Π²ΡΡΠΎΡΠ»ΠΈ ΠΏΡΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΎΠ±ΡΠ΅ΠΌΠΎΠ²Β ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ Π°Π½ΡΠΈΠ΄Π΅ΠΏΡΠ΅ΡΡΠ°Π½ΡΠΎΠ² ΠΈ ΡΡΠ°Π½ΠΊΠ²ΠΈΠ»ΠΈΠ·Π°ΡΠΎΡΠΎΠ²
Π€Π°ΡΠΌΠ°ΠΊΠΎΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π°, Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ°
cerebral infarction β is serious medical and social problem. Results of pharmacoepidemiological studies provide an objectiveΒ assessment of the quality of pharmacotherapy of brain infarction, and find out the rational use of drugs and to identify waysΒ to optimize the consumption of drugs. The results of pharmacoepidemiological analysis of drugs used for the treatment of cerebralΒ infarction in hospitals of various types, are presented. An assessment of compliance with national and international recommendationsΒ Β«is carried outΒ».ΠΈΠ½ΡΠ°ΡΠΊΡ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° β ΡΠ΅ΡΡΠ΅Π·Π½Π°Ρ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ ΠΈΒ ΡΠΎΡΠΈΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Β ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π°, Π²ΡΡΡΠ½ΠΈΡΡ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² ΠΈ Π½Π°ΠΌΠ΅ΡΠΈΡΡ ΠΏΡΡΠΈ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ ΠΌΠ΅Π΄ΠΈΠΊΠ°ΠΌΠ΅Π½ΡΠΎΠ². ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Β Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π° Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ
ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ°. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΠΈΡ
ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΡ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΠΈ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΌΒ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌ
ΠΠ½Π°Π»ΠΈΠ· ΡΡΡΡΠΊΡΡΡΡ Π·Π°ΡΡΠ°Ρ Π½Π° ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π° Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅ Π² 2009-2011 Π³Π³
Pharmacoeconomic analysis includes the assessment of direct cost structure in pharmacotherapy of cerebral infarction for the period of 2009-2011 in healthcare institutions in Saratov (762 patients) based on ABC analysis and frequency analysis. The results of the mentioned analysis showed the presence of drugs without proven efficacy and a very high associated cost component (75.67%) of purchasing budget in drug group Β«AΒ». It was revealed, that the drugs of scientifically substantiated efficacy and safety are not used sufficiently in treatment of cerebral infarction. On the other hand the drugs without proven efficacy are widely used, which leads to an increase in financial losses of the state and population. The results of clinical and economic analysis showed the need for changing the cost structure for drug therapy of the mentioned disease in hospitals.Π€Π°ΡΠΌΠ°ΠΊΠΎΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π²ΠΊΠ»ΡΡΠ°Π» ΠΎΡΠ΅Π½ΠΊΡ ΡΡΡΡΠΊΡΡΡΡ ΠΏΡΡΠΌΡΡ
Π·Π°ΡΡΠ°Ρ Π½Π° ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π° Π² 2009-2011 Π³ΠΎΠ΄Π°Ρ
Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΡΡ
Π»Π΅ΡΠ΅Π±Π½ΡΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡΡ
Π³. Π‘Π°ΡΠ°ΡΠΎΠ²Π° (762 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°) Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΠΠ‘- ΠΈ ΡΠ°ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΡΡΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π°Π»ΠΈΡΠΈΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ Β«ΠΒ» Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π±Π΅Π· Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΎΡΠ΅Π½Ρ Π²ΡΡΠΎΠΊΠ°Ρ Π΄ΠΎΠ»Ρ Π·Π°ΡΡΠ°Ρ Π½Π° Π½ΠΈΡ
(75,67%) ΠΎΡ Π±ΡΠ΄ΠΆΠ΅ΡΠ° Π·Π°ΠΊΡΠΏΠΎΠΊ. ΠΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΎΠ·Π³Π° ΠΈ ΠΈΠΌΠ΅ΡΡΠΈΡ
Π½Π°ΡΡΠ½ΠΎ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΠ΅ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΡΡΠ²Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ. ΠΠ°ΠΏΡΠΎΡΠΈΠ², ΡΠΈΡΠΎΠΊΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π±Π΅Π· Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΡΠΈΠ½Π°Π½ΡΠΎΠ²ΡΡ
ΠΏΠΎΡΠ΅ΡΡ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π° ΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΡΡΠΊΡΡΡΡ Π·Π°ΡΡΠ°Ρ Π½Π° ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ°Ρ
Π³ΠΎΡΠΎΠ΄Π°
- β¦